Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws,
SAN FRANCISCO, March 10, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk A/S (NYSE: NVO) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the prospects of it
NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
Novo Nordisk: CagriSema Disappoints Again
12:52pm, Monday, 10'th Mar 2025
Novo Nordisk: CagriSema Disappoints Again
Why Novo Nordisk Stock Is Falling Today
11:32am, Monday, 10'th Mar 2025
Shares of Novo Nordisk (NVO -8.70%) are tumbling on Monday. The company's stock lost 8.9% as of 10:10 a.m.
Novo Nordisk shares fall on weight-loss drug trial
11:16am, Monday, 10'th Mar 2025
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.
Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
11:03am, Monday, 10'th Mar 2025
Novo Nordisk A/S NYSE: NVO has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are no longer in short supply. This caused the United States Food and Drug Admini
Novo Nordisk shares fall on weight loss drug trial results
10:43am, Monday, 10'th Mar 2025
Novo Nordisk (NYSE:NVO) shares moved lower after the Danish drugmaker unveiled the latest trial results for its weight loss drug CagriSema. The Phase 3 trial, called Redefine 2, showed that CagriSema
Novo Nordisk Stock Drops on New Obesity Drug Finding. Eli Lilly Stands to Gain.
10:31am, Monday, 10'th Mar 2025
The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.
NVO Weight Loss Drug Disappoints, RDFN Acquisition, Airline Price Targets Slashed
10:30am, Monday, 10'th Mar 2025
Market weakness continued this morning, including in international companies like Novo Nordisk (NVO). Its next-gen weight loss drug trial results weren't enough to draw investors in.
Investors in Novo Nordisk A/S Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - NVO
10:15am, Monday, 10'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws,
Novo Nordisk Shares Sink on Latest CagriSema Weight Loss Drug Study
10:12am, Monday, 10'th Mar 2025
Novo Nordisk's (NVO) U.S.-listed shares fell Monday morning following the release of data for a new phase 3 clinical trial of its in-development weight loss drug CagriSema.
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordi
Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
09:10am, Monday, 10'th Mar 2025
SAN FRANCISCO, CA / ACCESS Newswire / March 10, 2025 / National plaintiffs law firm Lieff Cabraser Heimann & Bernstein, LLP encourages investors in Novo Nordisk A/S. ("Novo" or the "Company") (NYSE:NV
Novo Nordisk shares slide 6% after weight loss drug trial disappoints
07:59am, Monday, 10'th Mar 2025
Novo Nordisk shares declined on Monday after the company reported that its next-generation weight-loss drug, CagriSema, helped obese or overweight adult patients with type 2 diabetes reduce their weig
